These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16133115)

  • 21. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
    Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS
    J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ dendritic cell vaccination for the treatment of glioma and literature review.
    Li M; Han S; Shi X
    Tumour Biol; 2016 Feb; 37(2):1797-801. PubMed ID: 26318301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.
    Dey M; Chang AL; Miska J; Wainwright DA; Ahmed AU; Balyasnikova IV; Pytel P; Han Y; Tobias A; Zhang L; Qiao J; Lesniak MS
    J Immunol; 2015 Jul; 195(1):367-76. PubMed ID: 26026061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model.
    Kim JW; Kane JR; Panek WK; Young JS; Rashidi A; Yu D; Kanojia D; Hasan T; Miska J; Gómez-Lim MA; Ulasov IV; Balyasnikova IV; Ahmed AU; Wainwright DA; Lesniak MS
    Neurotherapeutics; 2018 Oct; 15(4):1127-1138. PubMed ID: 30027430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.
    Lasky JL; Panosyan EH; Plant A; Davidson T; Yong WH; Prins RM; Liau LM; Moore TB
    Anticancer Res; 2013 May; 33(5):2047-56. PubMed ID: 23645755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
    Belmans J; Van Woensel M; Creyns B; Dejaegher J; Bullens DM; Van Gool SW
    Sci Rep; 2017 Oct; 7(1):13902. PubMed ID: 29066810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Murine dendritic cells modified with CXCL10 gene and tumour cell lysate mediate potent antitumour immune responses in mice.
    Li B; Li Q; Zhao QL; Wei XB; Zhang XH; Wu CQ; Zhong CP
    Scand J Immunol; 2007 Jan; 65(1):8-13. PubMed ID: 17212761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
    Zhang H; Tian M; Xiu C; Wang Y; Tang G
    Oncol Res; 2013; 20(10):447-55. PubMed ID: 24308155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
    Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
    BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor efficacy of argon-helium cryoablation-generated dendritic cell vaccine in glioma.
    Yin Z; Lu G; Xiao Z; Liu T; He X; Wang Q; Lin C; Zhang S
    Neuroreport; 2014 Mar; 25(4):199-204. PubMed ID: 24445619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
    Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
    Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
    Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
    Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo.
    Rossowska J; Pajtasz-Piasecka E; Szyda A; Krawczenko A; Zietara N; Dus D
    Oncol Rep; 2009 Jun; 21(6):1539-49. PubMed ID: 19424635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.